Introduction
============

Granulomatosis with polyangiitis (GPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) resulting in a necrotizing small to medium vessels vasculitis and a necrotizing granulomatous inflammation involving predominantly the upper and lower respiratory tract and the kidneys. GPA is the result of a complex interplay between the humoral and cellular immunity involving proteinase 3-ANCA (PR3-ANCA), neutrophils, endothelial cells, B and T cells ([@ref-16]).

T cells are important in GPA as persistent activation of T cells through aberrant expression of costimulatory molecules favours the expansion of effector memory T cells and the formation of granuloma ([@ref-28]). Changes in T cells in GPA patients occur during remission when circulating memory T cells are increased and naive T CD4+ cells are decreased ([@ref-1]). Also, T cell-targeted therapies such as abatacept, alemtuzumab and gusperimus are alternative treatments to B cell depletion with rituximab (RTX) in GPA ([@ref-10]).

However, a subgroup of GPA patients has low CD4 cell count and inverted CD4/CD8 ratio irrespective of disease activity and the use of immunosuppressive drugs, possibly due to the recruitment of T cells into the inflamed tissue ([@ref-2]). It is not clear whether it is the decrease of CD4 cell count ([@ref-20]), the expansion of CD8 cell count or a combination of both ([@ref-13]; [@ref-14]) that is responsible for the inversion of the ratio.

RTX is a chimeric human-mouse monoclonal antibody directed against CD20 that induces rapid and sustained depletion of premature and mature B cells through antibody-dependent, complement-mediated cellular cytotoxicity and apoptosis ([@ref-18]). RTX reduces auto-antibody producing precursor plasma cells, inhibits B cell interaction with auto reactive T cells and decreases the level of soluble factors secreted by B cells ([@ref-18]). RTX is approved for the treatment of rheumatoid arthritis (RA) and AAV and is used off label in a large number of autoimmune conditions ([@ref-8]). In AAV, RTX is used to induce ([@ref-15]; [@ref-26]) and to maintain ([@ref-12]; [@ref-25]; [@ref-7]; [@ref-4]) remission through iterative infusions. Relevant side effects of RTX include late onset neutropenia ([@ref-3]), hypogammaglobulinemia ([@ref-19]; [@ref-5]) and an increased risk of infections ([@ref-4]; [@ref-22]; [@ref-23]; [@ref-11]). In two studies, 27--44% of all severe infections during RTX treatment were either viral or fungal ([@ref-4]; [@ref-19]), possibly related to T cell immunodeficiency.

Our study investigated the course of CD4 cell count, CD4/CD8 ratio and serum levels of total immunoglobulin (Ig) in GPA patients receiving long-term RTX treatment.

Methods
=======

The Vasculitis Registry in Northern Norway is an observational prospective registry collecting data on disease presentation and course from patients with an established diagnosis of primary vasculitis. All patients gave informed written consent at inclusion in accordance with the declaration of Helsinki.

A total of 35 patients from the Vasculitis Registry in Northern Norway with an established diagnosis of GPA were included in the study. The study did not require formal ethical approval and conformed to the standards currently applied in Norway. Patients' characteristics at baseline have been previously described ([@ref-4]).

At RTX initiation, the patients (median age of 50 (14--79), 54% males) had median disease duration of 55 months (1--270). However, 86% of the patients were ANCA positive; all except one were PR3-ANCA positive. Renal, lung and orbital or/and subglottic involvement was present in 60, 63 and 57% of the patients. Median Birmingham Vasculitis Activity Score (BVAS) was 9 (0--22) at baseline. The main indication for RTX was disease relapse (80%), new disease onset (17%) and maintenance therapy (3%). Patients had received a median cumulative cyclophosphamide (CYC) dose of 14 g (0--250) prior to RTX and all had normal total Ig levels (\> 6 g/l) prior to RTX.

Patients received 2 g RTX at induction (1 g twice in a fortnight) with co-administration of methylprednisolone 125 mg, paracetamol 1,000 mg and either cetirizine 10 mg or polaramine 4 mg. RTX was usually combined with a median oral daily prednisolone dose (ODPD) of 20 mg (0--60) and an immunosuppressive drug in 91% of the patients. Overall, patients received a median cumulative RTX dose of 4 g (2--6) during the first 24 months following its initiation. Respectively 49 and 40% received long-term maintenance with the 2 g annually regimen (1 g twice in a fortnight per year) or the 1 g biannually regimen (1 g every six months), while 11% received only induction.

Clinical parameters such as gender, age, erythrocyte sedimentation rate (ESR, nr: \< 20 in men and \< 28 mm/h in women), C-reactive protein (CRP, nr \< 5 mg/l), creatinine (nr: 60--105 in men and 45--90 μmol/l in women), ANCA titers (nr \< 10 IU/ml), the ODPD and the cumulative dose of CYC were recorded at baseline. Serum levels of total Ig and lymphocytes subsets were measured at RTX initiation and at 3, 6, 12, 18 and 24 months in 35, 24, 31, 34, 31 and 34 patients, respectively. CD4 and CD8 cell counts were determined by flow cytometry in blood specimens. Normal adult CD4 and CD8 cell counts for our laboratory ranged from 0.3--1.4 and 0.2--0.9 × 10^9^/l, respectively. Low CD4 cell count was defined as CD4 \< 0.3 × 10^9^/l and inverted CD4/CD8 ratio when ratio \< 1. Hypogammaglobulinemia was defined as serum total Ig \< 6 g/l. Severe infections were defined as infections necessitating intravenous antibiotic treatment and/or hospitalisation.

Data were analysed with SPSS version 20.0 (SPSS Ltd, Chicago, IL, USA). The results are expressed in percentage for categorical variable and in median (range) for continuous variables, unless specified otherwise. Fisher's exact test, Wilcoxon signed rank test and Man-Whitney U test were used as appropriate. Significant predictors of inversion of the CD4/CD8 ratio at 24 months determined during univariable analysis were entered in a multivariable binary logistic regression model with backward selection (p \< 0.05 to enter and p \< 0.10 to stay). Missing data were excluded from the statistical analyses. p-values \< 0.05 were considered significant.

Results
=======

CD4 cell count and ratio
------------------------

Both the CD4 cell count and the CD4/CD8 ratio decreased initially after RTX administration, and thereafter increased gradually ([Fig. 1](#fig-1){ref-type="fig"}). The CD4 cell count seemed to decrease between baseline and three months (0.36--0.28 × 10^9^/l, p = 0.166), while the ratio decreased significantly from 1.16 to 0.99 (p = 0.011). At 24 months, CD4 cell count and ratio had both significantly increased from baseline: 0.45 × 10^9^/l (p = 0.039) and 1.38 (p = 0.031), respectively.

![CD4 cell count and CD4/CD8 ratio in GPA patients during long-term RTX treatment.\
Full line: low CD4 cell count. Dashed line: inverted CD4/CD8 ratio. Table results are expressed in median and interquartile range.](peerj-04-2487-g001){#fig-1}

However, while the proportion of patients with a low CD4 cell count decreased from 43% at baseline to 18% at 24 months, the proportion of patients with inverted ratio remained stable around 40% throughout the study period ([Fig. 2](#fig-2){ref-type="fig"}).

![Proportion of GPA patients with low CD4 cell count and inverted ratio during long-term rituximab.\
Full line: low CD4 cell count. Dashed line: inverted CD4/CD8 ratio. The proportion of patients is expressed in percentage.](peerj-04-2487-g002){#fig-2}

Baseline clinical profile influence on CD4 cell count and ratio
---------------------------------------------------------------

### CD4 cell count and ratio at baseline

Patients with low CD4 cell count and inverted ratio at baseline had a tendency to be older (p = 0.069 and p = 0.057, respectively) ([Tables 1](#table-1){ref-type="table"} and [2](#table-2){ref-type="table"}). Only patients with low CD4 cell count seemed to have a higher cumulative dose of CYC compared with patients with a normal baseline CD4 cell count (p = 0.071) ([Table 2](#table-2){ref-type="table"}).
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###### Characteristics of GPA patients with low CD4 cell count at baseline against the rest of the cohort.

Results are expressed in number (percentage) for categorical variables and median (range) for continuous variables. Differences were determined respectively by Fisher's exact test and Mann Whitney U test. Serum total immunoglobulin level and CD4 cell count expressed respectively in g/L and × 10^9^/L. Significant results are highlighted in bold.
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                                   Low CD4 count           Normal CD4 count        p-value
  -------------------------------- ----------------------- ----------------------- --------------
  Male                             9 (40%)                 10 (50%)                0.784
  Age y                            58 (19--79)             47 (14--67)             0.069
  Disease duration prior RTX mo    93 (2--270)             45 (1--198)             0.254
  BVAS at baseline                 11 (4--21)              8.5 (0--21)             0.657
  ESR mm/t                         15 (3--118)             17 (7--100)             0.400
  CRP mg/L                         6 (4--135)              7.5 (4--127)            0.908
  Creatinine μmol/L                75 (46--244)            77 (43--819)            0.934
  ANCA titers IU/L                 7 (0--531)              8 (1--109)              0.780
  Kidney involvement               8 (53%)                 13 (65%)                0.511
  Lung involvement                 10 (67%)                12 (60%)                0.737
  Orbital-subglottic involvement   10 (67%)                10 (50%)                0.492
  ODPD mg                          25 (3--50)              20 (0--60)              0.458
  Total CYC dose g                 25 (0--250)             13 (0--68)              0.071
  Total RTX dose g                 4.0 (2--5)              4.0 (2--6)              0.780
  1 g biannually RTX regimen       6 (40%)                 8 (40%)                 1.00
  Baseline                                                                         
   Total Ig                        10.0 (8.2--18)          11.8 (6.7--21)          0.283
   HypoG                           0                       0                       NA
   CD4                             **0.21 (0.06--0.29)**   **0.61 (0.31--1.4)**    **\<0.001**
   Ratio                           **0.94 (0.27--2.3)**    **1.51 (0.55--3.0)**    **\<0.001**
  At three months                                                                  
   Total Ig                        7.3 (4.8--15)           8.7 (6.6--12)           0.247
   HypoG                           3 (25%)                 0                       0.096
   CD4                             0.17 (0.09--1.4)        0.32 (0.17--0.89)       0.064
   Ratio                           0.81 (0.34--1.5)        1.12 (0.26--2.4)        0.096
  At six months                                                                    
   Total Ig                        7.4 (4.5--16)           8.4 (4.1--12)           0.238
   HypoG                           3 (23%)                 2 (11%)                 0.374
   CD4                             **0.27 (0.16--0.57)**   **0.43 (0.24--0.93)**   **\< 0.001**
   Ratio                           **0.93 (0.38--1.3)**    **1.25 (0.42--4.5)**    **0.014**
  At 12 months                                                                     
   Total Ig                        7.1 (4.9--15)           8.5 (5.3--15)           0.158
   HypoG                           1 (7.1%)                2 (10%)                 1.00
   CD4                             **0.29 (0.17--0.64)**   **0.49 (0.19--1.4)**    **0.002**
   Ratio                           **0.85 (0.33--1.8)**    **1.4 (0.51--4.8)**     **0.010**
  At 18 months                                                                     
   Total Ig                        6.7 (4.7--17)           7.9 (4.9--14)           0.297
   HypoG                           3 (21%)                 1 (5.9%)                0.304
   CD4                             **0.35 (0.13--1.3)**    **0.49 (0.21--1.1)**    **0.042**
   Ratio                           **0.92 (0.40--1.9)**    **1.5 (0.53--6.0)**     **0.022**
  At 24 months                                                                     
   Total Ig                        6.7 (3.0--14)           7.5 (4.9--14)           0.179
   HypoG                           5 (33%)                 3 (16%)                 0.417
   CD4                             **0.35 (0.06--1.0)**    **0.70 (0.08--1.3)**    **0.021**
   Ratio                           0.84 (0.34--2.9)        1.40 (0.36--5.4)        0.120

**Note:**

ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham vasculitis activity score; CD, cluster of differentiation; CRP, C-reactive protein; CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; HypoG, hypogammaglobulinemia; Ig, immunoglobulins; mo, months; NA, not available; ODPD, oral daily prednisolone dose; RTX, rituximab.
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###### Characteristics of GPA patients with inverted ratio at baseline against the rest of the cohort.

Results are expressed in number (percentage) for categorical variables and median (range) for continuous variables. Differences were determined respectively by Fisher's exact test and Mann Whitney U test. Serum total immunoglobulin level and CD4 cell count expressed respectively in g/l and × 10^9^/l. Significant results are highlighted in bold.
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                                   Inverted ratio          Normal ratio            p-value
  -------------------------------- ----------------------- ----------------------- --------------
  Male                             6 (50%)                 13 (57%)                0.736
  Age years                        58 (37--79)             48 (14--75)             0.057
  Disease duration prior RTX mo    116 (2--270)            47 (1--198)             0.263
  BVAS at baseline                 10.5 (4--21)            8.0 (0--21)             0.482
  ESR mm/t                         29 (3--118)             15 (3--100)             0.548
  CRP mg/l                         20 (4--135)             6 (4--115)              0.310
  Creatinine μmol/l                76 (58--244)            75 (43--819)            0.694
  ANCA titers IU/ml                6 (0--531)              8 (1--213)              0.878
  Kidney involvement               8 (67%)                 13 (57%)                0.721
  Lung involvement                 8 (67%)                 14 (61%)                1.00
  Orbital-subglottic involvement   10 (83%)                15 (65%)                0.282
  ODPD mg                          23 (3--50)              23 (0--60)              0.719
  Total CYC dose g                 25 (0--250)             13 (0--79)              0.363
  Total RTX dose g                 4 (2--5)                4 (2--6)                0.263
  1 g biannually RTX regimen       5 (42%)                 9 (39%)                 1.00
  Baseline                                                                         
   Total Ig                        11.3 (8.3--18)          11.3 (6.7--21)          0.461
   HypoG                           0                       0                       NA
   CD4                             **0.22 (0.06--0.79)**   **0.49 (0.15--1.4)**    **0.005**
   Ratio                           **0.61 (0.27--0.97)**   **1.42 (1.0--3.0)**     **\< 0.001**
  At three months                                                                  
   Total Ig                        7.1 (4.8--15)           8.7 (5.0--12)           0.238
   HypoG                           1 (13%)                 2 (12%)                 1.00
   CD4                             0.20 (0.09--0.70)       0.29 (0.13--1.4)        0.264
   Ratio                           **0.46 (0.34--1.1)**    **1.12 (0.26--2.4)**    **0.002**
  At six months                                                                    
   Total Ig                        **6.7 (4.1--16)**       **9.1 (5.0--12)**       **0.017**
   HypoG                           3 (27%)                 2 (10%)                 0.310
   CD4                             **0.27 (0.16--0.42)**   **0.43 (0.18--0.93)**   **\< 0.001**
   Ratio                           **0.55 (0.38--1.1)**    **1.25 (0.65--4.5)**    **\< 0.001**
  At 12 months                                                                     
   Total Ig                        **6.6 (5.3--15)**       **9.2 (4.9--15)**       **0.021**
   HypoG                           1 (8.3%)                2 (9.1%)                1.00
   CD4                             **0.28 (0.19--0.39)**   **0.50 (0.17--1.4)**    **\< 0.001**
   Ratio                           **0.62 (0.33--1.3)**    **1.47 (0.77--4.8)**    **\< 0.001**
  At 18 months                                                                     
   Total Ig                        **6.5 (4.7--17)**       **8.6 (5.5--13)**       **0.012**
   HypoG                           3 (30%)                 1 (4.7%)                0.087
   CD4                             **0.34 (0.15--0.48)**   **0.48 (0.13--1.3)**    **0.026**
   Ratio                           **0.53 (0.40--1.0)**    **1.63 (0.60--6.0)**    **\< 0.001**
  At 24 months                                                                     
   Total Ig                        6.2 (3.0--14)           7.9 (4.0--14)           0.063
   HypoG                           5 (42%)                 3 (14%)                 0.098
   CD4                             **0.34 (0.06--1.02)**   **0.69 (0.13--1.3)**    **0.007**
   Ratio                           **0.56 (0.34--1.5)**    **1.64 (0.60--5.4)**    **\< 0.001**

**Note:**

ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham vasculitis activity score; CD, cluster of differentiation; CRP, C-reactive protein; CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; HypoG, hypogammaglobulinemia; Ig, immunoglobulins; mo, months; NA, not available; ODPD, oral daily prednisolone dose; RTX, rituximab.

There were no difference in organ involvements, disease duration prior to RTX, BVAS, CRP, ESR, creatinine and ANCA titers at RTX initiation between patients with normal and low CD4 cell count at baseline ([Table 1](#table-1){ref-type="table"}) and patients with normal and inverted ratio ([Table 2](#table-2){ref-type="table"}).

### CD4/CD8 ratio at 24 months

Patients who had an inverted CD4/CD8 ratio at 24 months were older (60 vs. 45 years, p = 0.003), had higher ESR (43 vs. 12 mm/h, p = 0.009) and creatinine (82 vs. 67 μmol/l, p = 0.018) at baseline. Although not significant, they also had a tendency to higher BVAS (11 vs. 8, p = 0.096), CRP (24 vs. 6 mg/l, p = 0.076) and ANCA titers (16 vs. 5 IU/ml, p = 0.089). Being older and having higher CRP and ESR at baseline significantly increased the risk of inverted CD4/CD8 ratio at 24 months during univariable analysis ([Table 3](#table-3){ref-type="table"}). Age was the most important predictor for inversion of the CD4/CD8 ratio at 24 months during the multivariable analysis ([Table 3](#table-3){ref-type="table"}). Being 10 years older at RTX initiation increased the risk by 2.5 times.
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###### Odds ratio for inverted CD4/CD8 ratio at 24 months in GPA patients receiving rituximab maintenance.

All values were determined at rituximab initiation and were analysed with an unadjusted and multivariable logistic regression models with backward Wald selection (removal if p \< 0.10). Significant results are highlighted in bold.
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                            Unadjusted analysis   Multivariable analysis                                           
  ------------------------- --------------------- ------------------------ ----------- ---------- ---------------- -----------
  Men                       1.06                  0.27--4.24               0.934                                   
  **Age (y)**               **1.10**              **1.02--1.18**           **0.012**   **1.09**   **1.01--1.18**   **0.027**
  Disease duration (mo)     1.01                  0.99--1.02               0.075       1.01       0.99--1.03       0.089
  BVAS                      1.13                  0.96--1.32               0.135                                   
  **ESR (mm/h)**            **1.03**              **1.00--1.05**           **0.024**   1.03       0.99--1.06       0.098
  **CRP (mg/l)**            **1.02**              **1.00--1.04**           **0.044**                               0.705
  Creatinine (μmol/l)       1.02                  0.99--1.05               0.081                                   0.164
  ANCA titers (IU/ml)       1.03                  0.98--1.08               0.184                                   
  ODPD (mg/d)               1.04                  0.98--1.09               0.138                                   
  CYC cumulative dose (g)   1.01                  0.99--1.03               0.388                                   
  IgG (g/l)                 1.13                  0.84--1.52               0.428                                   
  IgA (g/l)                 1.20                  0.50--2.93               0.682                                   
  IgM (g/l)                 2.21                  0.70--7.00               0.177                                   
  Total Ig (g/l)            1.11                  0.89--1.37               0.357                                   

**Note:**

ANCA, antineutrophil cytoplasmic antibodies; BVAS, Birmingham vasculitis activity score; CI, confidence interval; CRP, C-reactive protein; CYC, cyclophosphamide; ESR, erythrocyte sedimentation rate; Ig, immunoglobulins; mo, months; ODPD, oral daily prednisolone dose; OR, odds ratio; y, years.

Serum immunoglobulin levels
---------------------------

Serum total Ig levels in both patients with low CD4 cell count and inverted ratio were lower at all time points during RTX maintenance ([Tables 1](#table-1){ref-type="table"} and [2](#table-2){ref-type="table"}). This was only significant in patients with inverted ratio compared with patients with normal ratio at baseline ([Table 2](#table-2){ref-type="table"}). The different RTX maintenance regimens did not influence CD4 cell count, ratio and total Ig levels in the first two years ([Table 4](#table-4){ref-type="table"}).
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###### Characteristics of the GPA patients receiving RTX 1 g biannually as maintenance treatment compared with the rest of the cohort.

Differences between categorical and continuous variables are determined respectively by Fisher's exact test and Mann Whitney U test. Serum total immunoglobulin level and CD4 cell count expressed respectively in g/L and × 10^9^/L.
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                     1 g biannually regimen   Other regimens   p-value
  ------------------ ------------------------ ---------------- ----------
  Male               9 (64%)                  10 (48%)         0.491
  Age y              50                       47               0.702
  Total CYC dose g   43                       25               0.274
  Total RTX dose g   4.9                      3.7              \< 0.001
  Baseline                                                     
   Total Ig          12.2                     10.9             0.342
   HypoG             0                        0                NA
   CD4               0.39                     0.51             0.474
   Ratio             1.31                     1.37             0.881
  At three months                                              
   Total Ig          8.4                      8.6              0.426
   HypoG             3 (25%)                  0                0.096
   CD4               0.25                     0.46             0.194
   Ratio             0.80                     1.11             0.123
  At six months                                                
   Total Ig          8.8                      7.9              0.600
   HypoG             2 (15%)                  3 (16%)          1.00
   CD4               0.41                     0.41             0.667
   Ratio             1.51                     1.20             0.421
  At 12 months                                                 
   Total Ig          8.5                      8.9              0.594
   HypoG             1 (7.7%)                 2 (9.5%)         1.00
   CD4               0.45                     0.49             0.600
   Ratio             1.72                     1.32             0.834
  At 18 months                                                 
   Total Ig          8.3                      8.4              0.666
   HypoG             4 (31%)                  0                0.023
   CD4               0.37                     0.57             0.059
   Ratio             1.78                     1.41             0.953
  At 24 months                                                 
   Total Ig          7.5                      8.2              0.650
   HypoG             3 (21%)                  5 (25%)          1.00
   CD4               0.52                     0.61             0.522
   Ratio             1.91                     1.42             0.823

**Note:**

CD, cluster of differentiation; CYC, cyclophosphamide; HypoG, hypogammaglobulinemia; Ig, immunoglobulins; RTX, rituximab.

Severe infections in the first 24 months after RTX initiation
-------------------------------------------------------------

Two patients (5.7%) had severe infections during the study period three and four months after RTX initiation. One patient had sinusitis secondary to Pseudomonas aeruginosa and the other had Pneumocystis jiroveci pneumonia. They were men, aged 62 and 79 years old, who had received 250 and 25 g of CYC. They had low B cell (0.04 and 0.06 × 10^9^/l) and CD4 cell counts (0.17 and 0.26 × 10^9^/l), inverted ratio (0.35 and 0.43), but had normal serum levels of total Ig (11.2 and 12.6 g/l) at baseline. At the time of infection, CD4 cell count remained low (0.16 and 0.17 × 10^9^/l) and total Ig had declined by to 4.8 and 7.5 g/l, respectively.

CD4 cell count and ratio in GPA patients who did not receive RTX maintenance
----------------------------------------------------------------------------

Four GPA patients (two men and two women) with a median age of 65 (14--79) years who had received a cumulative dose of 3 g (0--25) g of CYC were only administered RTX at induction and did not receive RTX maintenance.

The CD4 cell count and ratio decreased from 0.54 (0.26--0.98) at baseline to 0.36 (0.34--0.63) × 10^9^/l at 24 months. The CD4/CD8 ratio decreased from baseline and became inverted at 24 months: from 1.4 (0.43--2.2) to 0.61 (0.45--2.0).

Discussion
==========

In GPA patients on long term RTX treatment, overall CD4 cell count and CD4/CD8 ratio initially decreased in the first three months and thereafter gradually increased independent of the ODPD at baseline, the CYC cumulative dose and the maintenance regimen. However in older patients, the inverted ratio at baseline remained unchanged after two years and was associated with lower levels of total Ig.

Early effect of rituximab on CD4 cell count
-------------------------------------------

Prior to RTX treatment, 34 and 43% of GPA patients had respectively inverted CD4/CD8 ratio and decreased absolute numbers of CD4 cells. Age and the cumulative CYC dose were the most closely associated parameters, although these were not found statistically significant in this small cohort.

During RTX treatment, the early decrease in CD4 cell count seemed dependent of the baseline CD4 count. The higher the CD4 cell count was at baseline, the more CD4 cell count declined at three months. GPA patients with normal CD4 cell count (mean 0.67 × 10^9^/L at baseline) had a 40% decrease at three months while GPA patients with low CD4 cell count (mean 0.19 × 10^9^/L at baseline) had an 89% increase.

The same pattern was observed in RA ([@ref-21]; [@ref-27]; [@ref-9]) and in systemic lupus erythematosus (SLE) patients ([@ref-24]), but not in renal transplantation ([@ref-17]). In RA, CD4 cell count decreased by 37% at three months from a mean of 1.25 × 10^9^/l at baseline ([@ref-21]), remained unchanged at four months from a mean of 0.93 × 10^9^/l at baseline ([@ref-27]) and increased by 14% from a mean of 0.63 × 10^9^/l at baseline during the first three months ([@ref-9]). SLE patients had a 46% increase in CD4 cell count one month after RTX initiation from a mean of 0.43 × 10^9^/l at baseline ([@ref-24]). However, there were no effect of a single dose of RTX (375 mg/m^2^) on the CD4 and CD8 cell counts as well as the percentage of the different CD4 cell subsets including regulatory T cells at three and 24 months in renal transplant recipients concomitantly treated with tacrolimus and mycophenolate mofetil during the first six months ([@ref-17]).

Rituximab failed to normalise the CD4/CD8 ratio at 24 months
------------------------------------------------------------

RTX induction and maintenance failed to normalise the CD4/CD8 ratio in GPA patients with an inverted ratio at baseline, although CD4 cell counts recovered. Being 10 years older at baseline doubled the risk of inversion of the CD4/CD8 ratio at 24 months. This suggests a relative increase in CD8+ lymphocytes in older GPA patients receiving RTX. Still, it remains unclear how absolute CD4 cell count and ratio related to changes in disease activity, subsets of CD4 and CD8 cells or the combination of toxic drug effects.

GPA patients with inverted ratio after 24 months of RTX maintenance seemed to have more disease activity prior to RTX, more kidney involvement and higher inflammation parameters, in accordance to a previous report from [@ref-14]. They also had lower serum Ig during the course of our study, suggesting a more profound B cell-depleting effect.

Limitations of the study
------------------------

Our results should be interpreted with caution given the small size of the study cohort and the inherent risk of selection bias. Most of our GPA patients received RTX for refractory and relapsing disease, indicating a selected group who had received high cumulative dose of CYC and prolonged corticosteroids exposure prior to RTX. In addition, we only followed CD4 and CD8 counts in patients, and did not study important T cell subsets such as regulatory T cells.

Conclusions
===========

Our study suggests that the early decrease in CD4 after induction with RTX seemed dependent of the baseline CD4 count. Overall, CD4 cell count and CD4/CD8 ratio in GPA patients increased over time during RTX with no discernible impact of other immunosuppressive therapy. Increase in CD4 was not always followed by an increase in CD4/CD8 ratio, especially for a subgroup of older patients whom CD4/CD8 ratio remained inverted. Inverted CD4/CD8 ratio associated with lower Ig levels during maintenance with RTX.

Our study suggest that GPA patients with inverted CD4/CD8 ratio seemed to have a more profound B cell-depleting effect of RTX and a relative increase in CD8+ lymphocytes. CD4/CD8 ratio could be an important marker of a patient's net status of immunodeficiency during RTX, since inverted CD4/CD8 ratio is a common surrogate marker of immunosenescence of impaired responses to vaccination and infections due to the loss of repertoire diversity ([@ref-6]).
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